Journal of clinical virology plus最新文献

{"title":"A rapid review of the epidemiology and combating strategies of hepatitis C virus infection in Ghana","authors":"Marcarious M. Tantuoyir ,&nbsp;Muhammed Camara ,&nbsp;Marjan Sohrabi ,&nbsp;SeyedAhmad SeyedAlinaghi ,&nbsp;Zahra Ahmadinejad","doi":"10.1016/j.jcvp.2024.100195","DOIUrl":"10.1016/j.jcvp.2024.100195","url":null,"abstract":"<div><div>The contribution of viral hepatitis including hepatitis C virus (HCV) to morbidity and death is thought to be substantial in Ghana and should be accorded greater attention. Scopus, PubMed, and Web of Science databases were searched, as well as the Google Scholar search engine, for primary studies published from 1995–2023 inclusive. We specifically searched for primary studies as well as studies using both quantitative and qualitative methodologies. The country lacks population-based studies and comprehensive national HCV surveillance systems, making it difficult to estimate the true burden of HCV accurately. The prevalence of HCV infection is estimated to be between 1.75 and 3.4 % in Ghana. The predominant HCV genotype in the country is genotype 2, followed by genotype 1. The prevalence of genotypes 4, 5, and 6 is very low or nonexistent in Ghana. Older age (&gt;50 years), male gender, and HCV genotype 1b are significantly associated with liver fibrosis and cirrhosis leading to hepatocellular carcinoma. Ghana is among the high-prevalence HCV infection countries. There is a high prevalence of cirrhosis among HCV-infected individuals, with older age and genotype 1b associated with an increased risk. Consequently, more efforts are needed to increase awareness and implementation of national guidelines.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100195"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142529509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HAART treatment with free provided medications for people living with HIV in Huzhou, China","authors":"Xiaofeng Li ,&nbsp;Zhaowei Tong ,&nbsp;Qingqiu Zeng ,&nbsp;Meiling Xu ,&nbsp;Bin Shen ,&nbsp;Wei Zhang ,&nbsp;Yan Zhang ,&nbsp;Weihong Wang ,&nbsp;Kefeng Qin","doi":"10.1016/j.jcvp.2024.100191","DOIUrl":"10.1016/j.jcvp.2024.100191","url":null,"abstract":"<div><h3>Background</h3><div>For antiretroviral therapy (ART), drug combinations have been freely provided to people living with human immunodeficiency virus (PLWH) for treatment of acquired immunodeficiency syndrome (AIDS)in China. We have systematically analyzed the treatment results in Huzhou, Zhejiang Province.</div></div><div><h3>Methods</h3><div>Total 724 patients with HIV antibody positive from May 2005 to March 2023 at the age of 40.4±15.4 (15-82) years were treated with free provided drug combinations, including lamivudine (3TC), efavirenz (EFV) and tenofovir (TDF), or drugs at patient's own expense, includingbictegravir (BIC), emtricitabine (FTC) and tenofovir alafenamide (TAF). CD4+ T-cell count and viral load (VL) were detected before and after HAART treatment.</div></div><div><h3>Results</h3><div>Before and after HAART treatment, CD4+ T-cell count and viral load (VL) were measured. CD4+ T-cell count in 724 PLWH was from 269.2±178.9 to 453.8±243.3 cells/µl (<em>p</em>=0.0001), with 627(86.60%) cases increasing (221.0±204.6 cells/µl), 63(8.70%) decreasing (-96.0±84.1 cells/µl), 54(7.46%) cases no change. At the end of the treatment, 251(34.67%) cases were with CD4+ T-cell count&gt;500.Viral load (VL)in 243 PLWHwas 14,474.4±62769.4 vs. 1,100.3±8513.1 copies/ml (<em>p</em>=0.0011), and with 181(74.49%) cases decreasing (-18,365.3±71,761.1 copies/ml), 14(5.76%) increasing (5,302.3±11,766.8 copies/ml), and 48 (19.75%) no change. Twenty-six patients died during the treatment period. There were no significant differences between results using free provided and paid drug combinations.</div></div><div><h3>Conclusion</h3><div>The free provided drug combinations increase CD4+ T-cell count and decrease viral load in PLWH, but about one-fourth of patients are considered as treatment failure. The improvement is needed for the HAART treatment.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100191"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142322935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serologic evidence of dengue and chikungunya among patients with acute febrile illness in Ghana, 2016 – 2018","authors":"Deborah Pratt ,&nbsp;Hayashi Takaya ,&nbsp;Abigail Akua Abankwa ,&nbsp;Yaw Awuku-Larbi ,&nbsp;Stephen Nyarko ,&nbsp;Esinam E Agbosu ,&nbsp;Magdalene Ofori ,&nbsp;Stella Bour ,&nbsp;Dennis Laryea ,&nbsp;Franklin Asiedu-Bekoe ,&nbsp;Toshihiko Suzuki ,&nbsp;Shoji Yamaoka ,&nbsp;Joseph Humphrey Kofi Bonney","doi":"10.1016/j.jcvp.2024.100193","DOIUrl":"10.1016/j.jcvp.2024.100193","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to describe the exposure levels to Dengue and Chikungunya viruses among individuals presenting with febrile illnesses in Ghana between January 2016 to June 2018.</div></div><div><h3>Methods</h3><div>The study was conducted in health facilities in seven selected regions in Ghana; namely, Ashanti, Greater Accra, Northern, Upper West, Volta, and Western regions. Patients who met the case definition were enrolled in the study. A total of 1105 blood samples were collected from patients from 2016 to 2018 and serological analysis of Dengue and Chikungunya viruses were performed with ELISA IgM and IgG commercial kits (Abcam, Cambridge, UK).</div></div><div><h3>Results</h3><div>Analysed results indicated that Dengue and Chikungunya viruses showed seropositivity of 62.0 % and 40.0 % respectively. All processed samples tested negative for Dengue and Chikungunya using the Polymerase Chain Reaction (PCR) assay. Greater Accra and Ashanti regions recorded the highest positivity for Chikungunya and Dengue fever viruses respectively.</div></div><div><h3>Conclusion</h3><div>Though no detection of Dengue and Chikungunya using molecular tools, the seropositivity suggests the need for an established surveillance for arboviruses to monitor transmission of these pathogens for epidemic preparedness and response.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100193"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142529510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next generation sequencing-based transcriptome data mining for virus identification and characterization: Review on recent progress and prospects","authors":"Mohammadreza Rahimian ,&nbsp;Bahman Panahi","doi":"10.1016/j.jcvp.2024.100194","DOIUrl":"10.1016/j.jcvp.2024.100194","url":null,"abstract":"<div><p>Advancements in next-generation sequencing (NGS) technologies and innovative bioinformatics tools have significantly accelerated virus discovery by analyzing of NGS data. This approach provides a cost-effective and efficient method for processing large datasets, allowing for rapid virus detection and identification. Researchers can comprehensively understand virus-host interactions by integrating data mining with other omics data, such as proteomics (the study of proteins) and metabolomics (the study of metabolic processes). Recent progress has significantly enhanced the efficiency and accuracy of virus identification by using a sophisticated NGS data mining approach. This study provides an in-depth discussion of these techniques, offering a detailed overview of workflows and applicable computational methods. Despite these advantages, the virus discovery process through data mining encounters obstacles such as ethical issues, the absence of standardized protocols for virus discovery procedures, and challenges in validation and interpretation. Addressing these obstacles is crucial for fully realizing the potential of NGS data mining in virus research. This review discusses current methodologies, recent advancements, and future directions to overcome these challenges, ultimately contributing to our understanding of viral diversity and virus-host dynamics.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100194"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703802400019X/pdfft?md5=8839daa94af23784c8bcda03aa8fc6a2&pid=1-s2.0-S266703802400019X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance evaluation of four kits for the detection of neutralizing antibody against SARS-CoV-2 in human serum","authors":"Hui Zhen ,&nbsp;Ya Cheng ,&nbsp;Qimeng Sun,&nbsp;Ying Zheng,&nbsp;Lili Tian,&nbsp;Chao Shen,&nbsp;Li Li,&nbsp;Jie Gong,&nbsp;Yonggang Chen,&nbsp;Hongping Ba","doi":"10.1016/j.jcvp.2024.100192","DOIUrl":"10.1016/j.jcvp.2024.100192","url":null,"abstract":"<div><p>To evaluate four novel SARS-CoV-2 neutralizing antibody assay kits' application in neutralizing antibodies of population. Questionnaires from the voluntary participating researchers and selected the qualified questionnaires to analyse. For negative and positive coincidence rate, four novel SARS-Cov-2 neutralization antibody assay kits were tested. For within-run and between-run Precision verification study, four serum samples with two high and two low titer neutralizing antibodies were used to analyse. Based on the questionnaires, 175 qualified samples were divided into two groups. (1) negative neutralizing antibodies group: 31 samples had not been infected with the novel SARS-Cov-2 nor received the vaccine within the past one year; (2) positive neutralizing antibodies group: 144 samples were infected by COVID-19. There was 28 negative and 3 positive neutralizing antibodies of the individuals among the 31 negative samples which based on the questionnaires. The negative rates of 28 negative individules tested by GenScript, Vazyme and Hygeianey were 82.14 %, 60.71 % and 17.85 %, while the positive rates of the 147 positive samples were 93.87 %, 95.23 % and 100 %. The within-run coefficient of variations (C·V) of PBNAs, GenScript, Vazyme and Hygeianey were 11.49 %, 9.12 %, 7.97 % and 7.48 %, while the between-run coefficient of variations (C·V) were 21.37 %, 14.21 %, 12.29 % and 11.78 %. Due to the large within-run and between-run coefficient of variations, PBNAs was not suitable for large-scale promotion, while ELISAs could be leveraged for routine monitoring the titer of neutralizing antibodies against SARS-CoV-2.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 4","pages":"Article 100192"},"PeriodicalIF":1.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000176/pdfft?md5=3e552214716ffe9cd0199a6acb5dc419&pid=1-s2.0-S2667038024000176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142270719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis E virus seroprevalence in patients with human immunodeficiency virus: A single-center study in Japan","authors":"Yoshitaka Wakabayashi ,&nbsp;Satoshi Kitaura ,&nbsp;Koh Okamoto ,&nbsp;Mahoko Ikeda ,&nbsp;Shintaro Yanagimoto ,&nbsp;Shu Okugawa ,&nbsp;Kyoji Moriya","doi":"10.1016/j.jcvp.2024.100185","DOIUrl":"10.1016/j.jcvp.2024.100185","url":null,"abstract":"<div><p>Hepatitis E virus (HEV) is a pathogen that causes hepatitis. There are few reports of HEV seroprevalence among people with human immunodeficiency virus (PWH) in Japan. This study aimed to determine the HEV seroprevalence among PWH at our hospital. Anti-HEV IgG was tested for using enzyme immunoassays and immunoblot assays. Clinical information was obtained from medical records and additional patient questionnaires. Sixty-eight PWH were included in this study. Four patients (5.9 %) showed HEV IgG seropositivity with both methods, while one patient (1.5 %) was seropositive using only the immunoblot assay, and three patients (4.4 %) were seropositive using only the enzyme immunoassay. There was a significant difference in age between anti-HEV IgG-seropositive and -negative individuals (median, 57.5 and 48.0 years, respectively; <em>p</em> = 0.012). There were no significant differences in the other clinical characteristics. Our results revealed that age is a risk factor for HEV infection among PWH.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100185"},"PeriodicalIF":1.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000103/pdfft?md5=172cdf96f56efbfdf4452bee471c978c&pid=1-s2.0-S2667038024000103-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141276776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular characterization of the genome of a new bunyavirus isolated in 2023 in Huzhou, China","authors":"Shili Song ,&nbsp;Zhang Shen ,&nbsp;Deshun Xu","doi":"10.1016/j.jcvp.2024.100188","DOIUrl":"10.1016/j.jcvp.2024.100188","url":null,"abstract":"<div><p>The novel bunyavirus (SFTSV) causes severe fever with thrombocytopenia syndrome (SFTS), which has a high mortality rate and poses a serious threat to public health. To investigate the genomic characteristics of SFTSV strains isolated in Huzhou, China, in 2023, we sequenced SFTSV isolates and constructed a phylogenetic tree, and analyzed their homologies, average genetic distances, and amino acid (aa) mutations using DNAstar and MEGA software. The two SFTSV strains belonged to genotypes A and D. The nucleotide (nt) and aa sequence similarities of the two strains were 96.61% and 98.64%, respectively. The nt and aa sequence homologies with human reference strains of the same genotypes were 94.44% and 97.28%, respectively. The nt and aa sequence homologies with syngeneic tick host reference strains were 94.56% and 97.96%, respectively. The two SFTSV isolates had different mutation rates in the L, M, and S proteins; the M protein exhibited the highest mutation rate. Further investigations of SFTSV are warranted to explore the distributions of its genotypes, as well as its nt and aa mutations.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100188"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000139/pdfft?md5=49f55ea12b1e5562ede24ca60f1f110c&pid=1-s2.0-S2667038024000139-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141845067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decrease of Tregs cells and increase of exhausted Treg cells as the predictors of COVID19 severity","authors":"Seyed Mehdi Mirniam ,&nbsp;Alireza Andalib ,&nbsp;Maedeh Radandish ,&nbsp;Ramin Sami ,&nbsp;Nafiseh Esmaeil","doi":"10.1016/j.jcvp.2024.100189","DOIUrl":"10.1016/j.jcvp.2024.100189","url":null,"abstract":"<div><h3>Background</h3><p>T cells and regulatory T cells (Tregs) play a critical role in viral infectious immunity. Exhaustion of T cells during infection and decreased Tregs both contribute to the exacerbation of the disease. In the present study, we assessed T cells and regulatory T cells of COVID-19 patients and a control group according to the expression of the PD-1 molecule.</p></div><div><h3>Methods</h3><p>Forty-two COVID-19 patients and 40 controls were enrolled in the study. In COVID-19 patients, blood samples were collected on the first day of their hospitalization. Regulatory T cells (CD4+, CD25+, FOXP3+), CD4+PD-1+, and PD-1+ regulatory T cells were assessed by flow cytometry.</p></div><div><h3>Results</h3><p>The percentage of CD4+PD-1 + <em>T</em> cells in COVID-19 patients was significantly higher compared to the control group (<em>P</em> &lt; 0.0001). The percentage of PD-1+ regulatory T cells was significantly increased in the patient group compared to the control group (<em>P</em> &lt; 0.0001). However, the Treg percentage was significantly decreased in the patient group compared to the control group (<em>P</em> &lt; 0.0001). The frequency of CD4+PD-1 + <em>T</em> cells, Tregs, and PD-1+ Tregs had acceptable sensitivity and specificity for assisting in the diagnosis of severe/critical COVID-19. The declined Tregs and enhanced CD4+CD25+, CD4+PD-1+, and PD-1 + <em>T</em> cells were associated with disease severity.</p></div><div><h3>Conclusion</h3><p>The decrease in Tregs and the increase in exhaustion of these cells and T cells play an important role in COVID-19 pathogenesis. These immune parameters could be used as meaningful indicators for assisting in the diagnosis of severe/critical COVID-19.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100189"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000140/pdfft?md5=1ee8e6941b4c1a8e09bfd15853f7398b&pid=1-s2.0-S2667038024000140-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141841499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis C virus infection in Iran: A review of current prevalence and preventive strategies from a developing country","authors":"Marcarious M. Tantuoyir ,&nbsp;Muhammed Camara ,&nbsp;Marjan Sohrabi ,&nbsp;SeyedAhmad SeyedAlinaghi ,&nbsp;Zahra Ahmadinejad","doi":"10.1016/j.jcvp.2024.100186","DOIUrl":"https://doi.org/10.1016/j.jcvp.2024.100186","url":null,"abstract":"<div><p>Despite recent efforts to control and eradicate the hepatitis C virus (HCV), Iran still faces significant gaps and challenges in HCV epidemiological data. Accurate prevalence estimates based on comprehensive and up-to-date evidence compilations are critical in eliminating the virus. We used a qualitative approach in summarizing the findings of the included studies. The prevalence of HCV is within the range of 1.26 % (1.02 - 1.56). The introduction of strict screening protocols for blood transfusions has significantly reduced the incidence of transfusion-related HCV transmission in recent years though unsafe injection practices, men who have sex with men (MSM), and injecting drug use are still the primary risk factors for transmission. Studies indicate that the predominant HCV genotype in the country is genotype 1a, closely followed by genotypes 3a and 1b. Population-based studies and comprehensive national HCV surveillance systems are lacking. More efforts are needed to ensure the sustainability of HCV screening and infection control programs in Iran.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100186"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000115/pdfft?md5=f793bc4f9a09752a6b9a94ae4eefe847&pid=1-s2.0-S2667038024000115-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141606547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Otitis media with effusion in patients with COVID-19: A single-center study in China","authors":"Feifan Li ,&nbsp;Weiguo Zhang ,&nbsp;Chengfang Chen ,&nbsp;Rongjun Man ,&nbsp;Huiming Yang ,&nbsp;Shudong Yu","doi":"10.1016/j.jcvp.2024.100187","DOIUrl":"10.1016/j.jcvp.2024.100187","url":null,"abstract":"<div><h3>Background</h3><p>The swift global spread of coronavirus disease 2019 (COVID-19), a respiratory ailment primarily marked by pulmonary symptoms, has been linked to the involvement of various organs, including the intestines, kidneys, throat, and ears. Otitis media with effusion (OME), often succeeding an upper respiratory tract infection, mirrors its incidence. As a respiratory infectious disease, it prompts the query of whether the COVID-19 pandemic has spurred an uptick in OME and whether the COVID-19 virus persists in middle ear effusion (MEE) for an extended period.</p></div><div><h3>Methods</h3><p>To gauge the incidence of OME in the population during the COVID-19 pandemic, a tailored questionnaire was disseminated and subsequently analyzed. Assessing the rise in OME incidence during the pandemic, we compared the proportion of OME cases in the otology outpatient department between pandemic and non-pandemic periods. Statistical analysis involved a <em>t</em>-test. Simultaneously, MEE was collected from patients with COVID-19-associated OME during the pandemic to ascertain the presence of SARS-CoV-2 in MEE via polymerase chain reaction.</p></div><div><h3>Results</h3><p>Based on the questionnaire data, the estimated OME incidence in the population is approximately 31.4 %. In contrast to the non-pandemic period, the percentage variation in the OME outpatient proportion was 71.4 % (<em>P</em> &lt; 0.05). Among the 61 MEE samples, 13 polymerase chain reaction results were positive, constituting 21.31 %. Nasopharyngeal swabs yielded negative results. Notably, only one patient experienced OME recurrence after 1 month of auripuncture.</p></div><div><h3>Conclusions</h3><p>COVID-19 can trigger an escalation in OME cases. Even when nasopharyngeal swabs show negative results, SARS-CoV-2 can endure in MEE for an extended duration, suggesting the potential for asymptomatic COVID-19 transmission and recurrence within the population.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 3","pages":"Article 100187"},"PeriodicalIF":1.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000127/pdfft?md5=a6c22a287e279a8d6ab27dc174027ab8&pid=1-s2.0-S2667038024000127-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141848063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}